These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26220844)

  • 21. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
    Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
    Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
    Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
    Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.
    Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP
    Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
    Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
    J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study.
    Berghmans T; Gourcerol D; Lafitte JJ; Kotsori K; Paesmans M; Scherpereel A; Leclercq N; Sculier JP;
    Lung Cancer; 2008 Sep; 61(3):378-84. PubMed ID: 18313792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.
    Peng Y; Wang L; Qing Y; Li C; Ren T; Li Q; Li M; Zhang S; Shan J; Wang G; Yang Z; Wang D
    Sci Rep; 2015 Dec; 5():17766. PubMed ID: 26656462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
    Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.